|
It may not be not so much genuine ignorance, but a "if they don't ask, don't tell" policy... but I have to move on to something better, and thanks for the encouragement.
I know Herceptin is expensive, and I still think it would be beneficial to the insurance companies too if some clinical trials for this group got off the ground.
Another question for us is, is something like Cellsearch reliable enough for early stage bc that it would be covered for periodic testing, instead of us and our oncs prophylactically putting us on Herceptin?
Or would it make more sense for those of us who are HER2+++ to be among the first to routinely receive the gene identification test to see if we are in the high-risk category, and if we are, then to routinely be given Herceptin prophylactically?
A.A.
|